Page 21 - Development Expense News Today

•Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021-Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. Our second quarter performance demonstrates the strength of our strategy and diversified business model, said Robert G. Kramer, president and chief executive officer of Emergent BioSolutions. Through continued investment and innovation, we will play an important role in ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Alkami Announces First Quarter 2021 Financial Results Alkami Technology, Inc.May 11, 2021 GMT PLANO, Texas, May 11, 2021 (GLOBE NEWSWIRE) -- Alkami Technology, Inc. (Nasdaq: ALKT) (“Alkami”), a leading cloud-based digital banking solutions provider for U.S.-based financial institutions, announced today results for its first quarter ending March 31, 2021. First Quarter 2021 Financial Highlights GA...

Beyond the disastrous first-quarter results, new CEO Bob Lyons has an ambitious long-term goal.

Overview Tennant Company is a world leader in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, after...

Share this article Share this article SAN FRANCISCO, May 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021. "We had a very strong start to the year, experiencing record daily volumes, and we expect that momentum to continue into the coming years," said Sean George, co-founder and chief executive officer of Invitae. "Genetic...

BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates - Full-year 2021 Financial Guidance Reaffirmed - Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan - Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec - FDA Review of Vosoritide Proceeding; PDUFA Target Action...

Share this article Share this article ResearchAndMarkets.coms offering. The Global Retail Point of Sale Market size is expected to reach $33.8 billion by 2026, rising at a market growth of 14.1% CAGR during the forecast period. Point of Sale (POS) is a place where buyers can carry out the payment for any goods or service and can also pay. The POS terminals & systems are utilized in physical spaces to initiate card payments. Points of sale are the main center of attraction for the marketers as c...

Apr 6, 2021 at 6:20AM Follow @jimhalley Johnson & Johnson (NYSE:JNJ) is the very definition of a value stock: five consecutive years of annual revenue growth, an above-average dividend that has been raised for 58 consecutive years in a row, and a diversified product portfolio capable of weathering various lawsuits, pandemics, and whatever else gets thrown its way. Last week, it was reported that a batch of 15 million doses of the companys vaccine that was bei...

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021 Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021 Entered U.S. licensing and supply agreement for Riluzole Oral Film for treatment of ALS with Mitsubishi Tanabe Pharma America Sympazan ® (...

- Full-year 2020 Total Revenues Increased 9% to $1.86 billion - Company Dose-escalates in PHEarless, a Phase 1/2 Study with BMN 307 Gene Therapy for the Treatment of Phenylketonuria (PKU); the Third Potential Therapeutic Modality in its PKU Franchise - During the Fourth Quarter, BioMarin Announced Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study - Marketing Applications for Vosoritide to Treat Children with Achondroplasia u...